2025-10-14 - Analysis Report
Okay, here's an analysis of SDGR (Schrodinger Inc.) based on the provided data. I'll present the data with a brief numerical summary, followed by analysis.

**Report on Schrodinger Inc. (SDGR)**

**Company Overview:** Schrodinger Inc. is a company that develops software for drug discovery and materials science.

**1. Performance vs. S&P 500 (VOO)**

*   **SDGR Cumulative Return:** -52.70%
*   **VOO (S&P 500) Cumulative Return:** 64.84%
*   **Absolute Divergence (Current):** -120.9
*   **Relative Divergence:** 0.0 (This indicates SDGR is currently at the very bottom of its historical divergence range relative to the S&P 500.)

**Analysis:** SDGR has significantly underperformed the S&P 500 over the period examined.  The large negative divergence and relative divergence of 0.0 suggests that SDGR's performance is very weak compared to the benchmark.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
| ---------- | ------- | ----- | ------- | ------ | ------ |
| 2020-2022  | -70.0%  | 78.2% | -76.0%  | 0.0    | 1.4    |
| 2021-2023  | -57.0%  | 81.0% | -59.0%  | -0.0   | 2.6    |
| 2022-2024  | 6.0%    | 81.0% | -14.0%  | -0.0   | 1.4    |
| 2023-2025  | -1.0%  | 82.6% | -62.0%  | -0.0   | 1.4    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) is negative for most periods, indicating poor investment returns.
*   **MDD:** High Maximum Drawdown (MDD) values suggest significant potential for losses.
*   **Alpha:** Consistently negative Alpha values indicate underperformance relative to the benchmark, even after adjusting for risk.
*   **Beta:** A Beta near 0 suggests that SDGR's price movements are not strongly correlated with the overall market (S&P 500).
*   **Cap(B):** The capitalization fluctuates indicating that it is either growing as a company or potentially reducing its shares.

**2. Recent Price Action**

*   **Current Price:** \$19.70
*   **Last Market Data:** Price: \$19.7, Previous Close: \$19.08, Change: 3.25%
*   **5-day Moving Average:** 19.796
*   **20-day Moving Average:** 19.8298
*   **60-day Moving Average:** 19.9009

**Analysis:** The stock price experienced a 3.25% increase in the last trading session. The current price is slightly below all the moving averages, which may suggest continued downside pressure, but the recent price increase provides a counter signal.

**3. Indicators**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 53.95 (Neutral)
*   **PPO:** -0.31 (Slightly Negative)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (47 shares - Very Safe - MRI:0.90) Monthly invest 1.4% of total investment (\$1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **20-day Relative Divergence Change:** -3.4 (Short-term Decrease)
*   **Expected Return (%):** -6232.1% (Significant Underperformance Expected)

**Analysis:**

*   The MRI indicates a medium level of investment suitability based on risk.
*   RSI is around 50, indicating a neutral condition, neither overbought nor oversold.
*   PPO is slightly negative, suggesting the stock is in a slight downtrend.
*   The recent price increase (3.25%) may indicate a short-term positive movement but also potential volatility.
*   The dramatically negative expected return signals very high risk and potential for continued underperformance versus the S&P 500.
*   Hybrid Signal indicates that the stock is in a "buy" zone.

**4. Recent News & Significant Events:**

*   **Inducement Grants:** Standard news regarding stock options or restricted stock units granted to employees. Generally not a major market mover.
*   **Valuation Evaluation:** Articles evaluating the valuation suggest uncertainty and ongoing debate about the stock's worth.
*   **Analyst Rally Expectations:** Some analysts predict a potential rally, providing a potentially positive outlook.
*   **Conference Presentation:** Presenting at a healthcare conference could be a chance to gain visibility.
*   **Program Discontinuation:** Discontinuing a program is generally negative, suggesting setbacks in research and development.

**Analysis:** The news is mixed, with some positive analyst sentiment but also concerning news about program discontinuation.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Recommendation:** 1.56 (Buy)
*   **Target Price:** \$27.00 (Average)

**Analysis:** Analysts are generally positive on the stock, with a buy consensus and a target price significantly higher than the current price. However, note the low target price of $19, suggesting some analysts are pessimistic.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출     |
| ---------- | ----- | -------- |
| 2025-08-06 | -0.59 | 0.05 B\$ |
| 2025-05-07 | -0.82 | 0.06 B\$ |
| 2024-11-12 | -0.52 | 0.04 B\$ |
| 2024-07-31 | -0.74 | 0.05 B\$ |
| 2025-08-06 | -0.74 | 0.05 B\$ |

**Analysis:** Schrodinger is consistently reporting negative EPS (Earnings Per Share), which is a concern. Revenue is relatively stable but not high enough to offset costs.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
| ---------- | ------- | ------------- |
| 2025-06-30 | \$0.05B | 47.77%        |
| 2025-03-31 | \$0.06B | 52.26%        |
| 2024-12-31 | \$0.09B | 72.61%        |
| 2024-09-30 | \$0.04B | 50.24%        |
| 2024-06-30 | \$0.05B | 66.20%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE       |
| ---------- | ------- | --------- |
| 2025-06-30 | \$0.34B | -12.59%   |
| 2025-03-31 | \$0.37B | -16.01%   |
| 2024-12-31 | \$0.42B | -9.54%    |
| 2024-09-30 | \$0.45B | -8.49%    |
| 2024-06-30 | \$0.47B | -11.40%   |

**Analysis:**

*   **Revenue:** Revenue is variable, with a peak in Q4 2024.
*   **Profit Margin:** Profit margins are strong, indicating good efficiency in generating profit from revenue. However, this is not translating into overall profitability due to other expenses.
*   **Equity:** Equity is decreasing, which can be a sign of financial stress.
*   **ROE:** Negative Return on Equity (ROE) confirms that the company is not generating profits from shareholders' investments.

**7. Overall Summary**

Schrodinger (SDGR) presents a mixed picture. The stock has significantly underperformed the S&P 500, with negative Alpha and high MDD. Recent earnings show consistent losses. Revenue is inconsistent. Analysts have a "Buy" consensus, but this contrasts sharply with the company's poor financial performance and negative outlook. A program discontinuation is a concern.
**Recommendation:** The data suggests a cautious approach. While analysts are optimistic, the financial metrics and historical performance raise significant concerns. Further due diligence is needed before considering an investment.
